Cited by 1,752Phagocytosis and Immune RegulationAcute Myeloid Leukemia ResearchFlavonoids in Medical Research

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Open access

Majeti, Ravindra, Chao, Mark P., Alizadeh, Ash A., Pang, Wendy W., Jaiswal, Siddhartha, Gibbs, Kenneth D., van Rooijen, Nico, Weissman, Irving L.·2009·Cell

DOI 10.1016/j.cell.2009.05.045PMC PMC2726837

Open this paper in CoChat — free account

Abstract

Acute myeloid leukemia (AML) is organized as a cellular hierarchy initiated and maintained by a subset of self-renewing leukemia stem cells (LSC). We hypothesized that increased CD47 expression on human AML LSC contributes to pathogenesis by inhibiting their phagocytosis through the interaction of CD47 with an inhibitory receptor on phagocytes. We found that CD47 was more highly expressed on AML LSC than their normal counterparts, and that increased CD47 expression predicted worse overall survival in three independent cohorts of adult AML patients. Furthermore, blocking monoclonal antibodies directed against CD47 preferentially enabled phagocytosis of AML LSC and inhibited their engraftment in vivo. Finally, treatment of human AML LSC-engrafted mice with anti-CD47 antibody depleted AML and targeted AML LSC. In summary, increased CD47 expression is an independent, poor prognostic factor that can be targeted on human AML stem cells with blocking monoclonal antibodies capable of enabling phagocytosis of LSC.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2009.05.045

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Self-citation
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
Grimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P., Zheleznyak, A., Fang, Y., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,975
Cancer Stem Cells
Jordan, C. T., Guzmán, M. L., & Noble, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061808 · Cited by 1,748
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578
Self-citation
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 2×
“Consistent with this hypothesis, we have shown that pre-leukemic mutations occur in a clonal HSC population, eventually leading to the development of LSC at the MPP stage in AML or the granulocyte-macrophage progenitor (GMP) stage in myeloid blast crisis chronic myeloid leukemia (CML) (Jamieson et al., 2004; Miyamoto…”
BackgroundSelf-citation
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452

Flagged first, then by citations

Show all 47 references

1 of the 47 references couldn’t be matched to a known paper.

Sorted by citations

Items 901–1,000 of 1,001

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics
Roussel, X., Daguindau, É., Berceanu, A., Desbrosses, Y., Warda, W., Rocha, M. N. D., Trad, R., Deconinck, É., Deschamps, M., & Ferrand, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599933 · Cited by 24
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
Panuciak, K., Margas, M., Makowska, K., & Lejman, M. (2022) · Cells · doi:10.3390/cells11010139 · Cited by 22
QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment
Bresser, K., Logtenberg, M. E. W., Toebes, M., Proost, N., Sprengers, J., Siteur, B., Boeije, M., Kroese, L. J., & Schumacher, T. N. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2049486 · Cited by 22
CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Allouch, A., Voisin, L., Zhang, Y., Raza, S. Q., Lécluse, Y., Calvo, J., Selimoglu‐Buet, D., de Botton, S., Louache, F., Pflumio, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34548-3 · Cited by 25
Vaccines Targeting Cancer Stem Cells
Dhodapkar, M. V., & Dhodapkar, K. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e730 · Cited by 22
Targeting Myeloid Leukemia Stem Cells
Jordan, C. T. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000914 · Cited by 22
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation
Pantoja, D. R. S. (2011) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000105 · Cited by 22
Current Strategies in Immunotherapy for Acute Myeloid Leukemia
Lichtenegger, F. S., Schnorfeil, F. M., Hiddemann, W., & Subklewe, M. S. (2012) · Immunotherapy · doi:10.2217/imt.12.145 · Cited by 22
Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity
Yanagisawa, B. L., Ghiaur, G., Smith, B. D., & Jones, R. J. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.08.010 · Cited by 22
CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies
Xu, L., Wang, S., Li, J., & Li, B. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.175 · Cited by 22
Role of Microenvironment in Non-Hodgkin Lymphoma
Khurana, A., & Ansell, S. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000446 · Cited by 23
Checkpoint CD47 expression in classical Hodgkin lymphoma
Gholiha, A. R., Hollander, P., Löf, L., Glimelius, I. C., Hedström, G., Molin, D. L., Hjalgrim, H., Smedby, K. E. E., Hashemi, J., Amini, R., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18137 · Cited by 22
Flower-Shaped Lipid Nanoparticles Evade Apolipoprotein E-Mediated Liver Tropism for Safe and Enhanced Cytokine-Based Cancer Immunotherapy
Qi, Y., Fu, Y., Wu, X., Chen, Z., Tang, Y., Ao, H., Zhu, H., Zou, C., Sun, B., Zheng, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c11552 · Cited by 23
Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs
Tomei, S., Ibnaof, O., Ravindran, S., Ferrone, S., & Maccalli, C. (2021) · Cancers · doi:10.3390/cancers13071674 · Cited by 21
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
Ikeda, D., Chi, S., Uchiyama, S., Nakamura, H., Guo, Y., Yamauchi, N., Yuda, J., & Minami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115950 · Cited by 21
CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer
Duan, Y., Li, S., Huang, B., Dou, Y., Kong, P., Kang, W., & Xu, D. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109238 · Cited by 21
The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
Xu, J., Shi, Q., Wang, B., Ji, T., Guo, W., Ren, T., & Tang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257254 · Cited by 21
Checkpoint inhibition in hematologic malignancies
Tsumura, A., Levis, D. J., & Tuscano, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288172 · Cited by 22
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer
Zhang, K., Xu, Y., Chang, X., Xu, C., Xue, W., Ding, D., Nie, M., Cai, H., Xu, J., Zhan, L., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03667-9 · Cited by 21
Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
Natan, T., Gur‐Wahnon, D., Adi, B.-Y., & Rachmilewitz, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075595 · Cited by 22
Pinellia pedatisecta Agglutinin Targets Drug Resistant K562/ADR Leukemia Cells through Binding with Sarcolemmal Membrane Associated Protein and Enhancing Macrophage Phagocytosis
Chen, K., Yang, X., Wu, L., Yu, M., Li, X., Li, N., Wang, S., & Li, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074363 · Cited by 21
Perspectives on anti-CD47 antibody treatment for experimental cancer
Unanue, E. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308463110 · Cited by 21
Human Acute Myelogenous Leukemia Stem Cells Revisited - There's More Than Meets the Eye
Majeti, R., & Weissman, I. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.007 · Cited by 26
Self-citation
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy
Xu, M. M., Pu, Y., Weichselbaum, R. R., & Fu, Y. (2016) · Oncogene · doi:10.1038/onc.2016.231 · Cited by 21
Key Issues Related to Cryopreservation and Storage of Stem Cells and Cancer Stem Cells: Protecting Biological Integrity
Karimi‐Busheri, F., Rasouli‐Nia, A., & Weinfeld, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-45457-3_1 · Cited by 21
B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways
Xia, F., Zhang, Y., Xie, L., Jiang, H., Zeng, H., Chen, C., Liu, L., He, X., Hao, X., Fang, X., et al. (2017) · Leukemia · doi:10.1038/leu.2017.232 · Cited by 21
Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice
Abe, T., Tanaka, Y., Piao, J., Tanimine, N., Oue, N., Hinoi, T., García, N. V., Miyasaka, M., Matozaki, T., Yasui, W., et al. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12205 · Cited by 21
Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T‐cell leukemia/lymphoma
Yanagida, E., Miyoshi, H., Takeuchi, M., Yoshida, N., Nakashima, K., Yamada, K., Umeno, T., Shimasaki, Y., Furuta, T., Seto, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2768 · Cited by 21
Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
Valent, P., Bauer, K., Sadovnik, I., Smiljkovic, D., Ivanov, D., Herrmann, H., Filik, Y., Eisenwort, G., Sperr, W. R., & Rabitsch, W. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0147 · Cited by 21
Heat Shock Proteins in Lymphoma Immunotherapy
Albakova, Z., Mangasarova, Y., & Sapozhnikov, A. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660085 · Cited by 22
Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence
Li, J., Sun, Z., Cui, Y., Qin, L., Wu, F., Li, Y., Du, N., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913740 · Cited by 23
Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms
Valent, P., Sadovnik, I., Eisenwort, G., Herrmann, H., Bauer, K., Mueller, N., Sperr, W. R., Wicklein, D., & Schumacher, U. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.025 · Cited by 21
Blockade of CD47 or SIRPα: a new cancer immunotherapy
Murata, Y., Saito, Y., Kotani, T., & Matozaki, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1811855 · Cited by 20
Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 production
Zhong, C., Wang, L., Hu, S., Huang, C., Xia, Z., Liao, J., Yi, W., & Chen, J. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ma0421-013r · Cited by 23
Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
Huang, B. Y., Bai, Z., Ye, X., Zhou, C., Xie, X., Zhong, Y., Lin, K., & Ma, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.036 · Cited by 20
In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies
Mercier, F., Shi, J., Sykes, D. B., Oki, T., Jankovic, M., Man, C. H., Kfoury, Y. S., Miller, E., He, S., Zhu, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007250 · Cited by 22
Myc inhibition tips the immune balance to promote antitumor immunity
Yang, C., Liu, Y., Hu, Y., Fang, L., Huang, Z., Cui, H., Xie, J., Hong, Y., Chen, W., Xiao, N., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00898-7 · Cited by 20
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 22
Self-citation
Therapeutic targeting of leukemia stem cells in acute myeloid leukemia
Barbosa, K., & Deshpande, A. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1204895 · Cited by 20
The cross-talk between macrophages and tumor cells as a target for cancer treatment
Aizaz, M., Khan, A. U., Khan, F., Khan, M., Saleh, E. A. M., Nisar, M., & Baran, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1259034 · Cited by 24
Imaging of CD47 Expression in Xenograft and Allograft Tumor Models
Zheleznyak, A., Ikotun, O. F., Dimitry, J. M., Frazier, W. A., & Lapi, S. E. (2013) · Molecular Imaging · doi:10.2310/7290.2013.00069 · Cited by 20
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
Stahl, M. F., Kim, T. K., & Zeidan, A. M. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i10.316 · Cited by 20
CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells
Abé, H., Saito, R., Ichimura, T., Iwasaki, A., Yamazawa, S., Shinozaki‐Ushiku, A., Morikawa, T., Ushiku, T., Yamashita, H., Seto, Y., et al. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2332-2 · Cited by 21
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
Zhang, J., Jin, S., Guo, X., & Qian, W. (2018) · Journal of International Medical Research · doi:10.1177/0300060518799612 · Cited by 20
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis
Verhagen, H. J. M. P., van Gils, N., Martiáñez, T., van Rhenen, A., Rutten, A. P., Denkers, F., de Leeuw, D. C., Smit, M. A., Tsui, M.-L., Klootwijk, L. L. E. D. V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.062 · Cited by 20
Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions
Tan, Y., Wu, Q., & Zhou, F. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102993 · Cited by 20
CD47 blockade reduces the pathologic features of experimental cerebral malaria and promotes survival of hosts with Plasmodium infection
Dulgeroff, L. B. T., Oakley, M. S., Tal, M. C., Yiu, Y. Y., He, J. Q., Shoham, M., Majam, V., Okoth, W. A., Malla, P., Kumar, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907653118 · Cited by 20
Self-citation
Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells
Zimarino, C., Moody, W., Davidson, S. E., Munir, H., & Shields, J. D. (2024) · iScience · doi:10.1016/j.isci.2024.109546 · Cited by 19
Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
Zhao, J., Hu, S., Qi, Z., Xu, X., Long, X., Huang, A., Liu, J., & Cheng, P. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009768 · Cited by 19
Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis
Ooki, A., Osumi, H., Shimozaki, K., & Yamaguchi, K. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10269-z · Cited by 19
Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy
Song, F., Lin, S., Xu, T., Yang, C., Sharavyn, B., Naranmandura, H., Zhang, Y., & Huang, P. C. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101286 · Cited by 21
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
Rashidi, A., & Walter, R. B. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1142868 · Cited by 19
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies
Rotiroti, M. C., Arcangeli, S., Casucci, M., Perriello, V. M., Bondanza, A., Biondi, A., Tettamanti, S., & Biagi, E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.092 · Cited by 19
Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Palacios‐Berraquero, M. L., & Piérola, A. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102107 · Cited by 19
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 20
Targeting tumor microenvironment and metastasis in children with solid tumors
Wessel, K. M., & Kaplan, R. N. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001082 · Cited by 20
Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
Hansen, Q., Bachas, C., Smit, L., & Cloos, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.140 · Cited by 21
Present and Future Role of Immune Targets in Acute Myeloid Leukemia
Damiani, D., & Tiribelli, M. (2022) · Cancers · doi:10.3390/cancers15010253 · Cited by 19
Organogermanium THGP Induces Differentiation into M1 Macrophages and Suppresses the Proliferation of Melanoma Cells via Phagocytosis
Azumi, J., Takeda, T., Shimada, Y., Zhuang, T., Tokuji, Y., Sakamoto, N., Aso, H., & Nakamura, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031885 · Cited by 19
Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
Aroldi, A., Mauri, M., Ramazzotti, D., Villa, M., Malighetti, F., Crippa, V., Cocito, F., Borella, C., Bossi, E., Steidl, C., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17868 · Cited by 19
Immunogenicity of cancer cells: An overview
Singh, T., Bhattacharya, M., Mavi, A. K., Gulati, A., Rakesh, Sharma, N. K., Gaur, S., & Kumar, U. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110952 · Cited by 20
CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance
Banuelos, A. M., Zhang, A., Berouti, H., Baez, M., Yılmaz, L., Georgeos, N., Marjon, K. D., Miyanishi, M., & Weissman, I. L. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318534121 · Cited by 19
Self-citation
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169315 · Cited by 19
Macrophage-based cancer immunotherapy: Challenges and opportunities
Bai, H., Feng, L., & Schmid, F. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114198 · Cited by 22
Cell Fusion In Tumor Development: Accelerated Genetic Evolution
Harkness, T., Weaver, B. A. A., Alexander, C. M., & Ogle, B. M. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v18.i1-2.30 · Cited by 19
Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design
Wouters, R., Cucchi, D. G. J., Kaspers, G. J. L., Schuurhuis, G. J., & Cloos, J. J. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.959921 · Cited by 19
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
Daga, S., Rosenberger, A., Kashofer, K., Heitzer, E., Quehenberger, F., Halbwedl, I., Graf, R., Krisper, N., Prietl, B., Höfler, G., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25918 · Cited by 19
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia
Eisenwort, G., Sadovnik, I., Keller, A., Ivanov, D., Peter, B., Berger, D., Stefanzl, G., Bauer, K., Slavnitsch, K., Greiner, G., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01227-z · Cited by 19
Exosome‐Coated Zeolitic Imidazolate Framework Nanoparticles for Intracellular Detection of ATP †
Lv, W., Han, Z., Li, Y., Huang, Y., Sun, J., Lu, X., & Liu, C. (2021) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202100162 · Cited by 19
Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
Wu, Z.-H., Li, N., Mei, X.-F., Chen, J., Wang, X., Guo, T., Chen, G., Nie, L., Chen, Y., Jiang, M.-Z., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004054 · Cited by 19
Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches
Thakral, D., Gupta, R., & Khan, A. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10349-5 · Cited by 19
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Golubovskaya, V. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2704121 · Cited by 19
Targeting of apoptosis gene loci by reprogramming factors leads to selective eradication of leukemia cells
Wang, Y., Lü, T., Sun, G., Zheng, Y., Yang, S., Zhang, H., Hao, S., Liu, Y., Ma, S., Zhang, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13411-y · Cited by 20
Cancer cell membrane-coated siRNA-Decorated Au/MnO2 nanosensitizers for synergistically enhanced radio-immunotherapy of breast cancer
Wang, D., Lin, S., Li, T., Yang, X., Zhong, X., Chen, Q., Jiang, G., & Li, C. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101275 · Cited by 18
Tumor‐Associated Macrophages Nano‐Reprogrammers Induce “Gear Effect” to Empower Glioblastoma Immunotherapy
Wang, Y., Li, G., Su, J., Liu, Y., Zhang, X., Zhang, G., Wu, Z., Li, J., Wang, X., Zhang, Y., et al. (2025) · Small · doi:10.1002/smll.202406839 · Cited by 18
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy
Guo, Z., Ataran, A., Ma, P., Yu, W., Hajirezaei, H., Ripoll, C. V., Pedersen, L. N., Rashidi, O., Chan, M. M., Shen, M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.071217 · Cited by 18
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
Chung, J., Vallurupalli, M., Noel, S., Schor, G., Mrowka, S., Scapozza, I., Demere, Z., Kammula, S. V., Hu, M., Kim, S. Y., et al. (2026) · Science · doi:10.1126/science.ady5196 · Cited by 18
A User’s Guide to Novel Therapies for Acute Myeloid Leukemia
Patel, S. A., & Gerber, J. M. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.011 · Cited by 18
Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture
Hassan, E. M., Walker, G. C., Wang, C., & Zou, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02728-z · Cited by 18
Diversity of the Origin of Cancer Stem Cells in Oral Squamous Cell Carcinoma and Its Clinical Implications
Fukumoto, C., Uchida, D., & Kawamata, H. (2022) · Cancers · doi:10.3390/cancers14153588 · Cited by 18
LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
Hu, J., Dong, F., He, Y., Xia, X., Cheng, F., Chen, S., Hou, X., Zhang, P., Liu, G., Li, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004452 · Cited by 18
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
Georgoulis, V., Papoudou‐Bai, A., Makis, A. C., Kanavaros, P., & Hatzimichael, E. C. (2023) · Biology · doi:10.3390/biology12060862 · Cited by 19
Application of cell membrane-functionalized biomimetic nanoparticles in the treatment of glioma
Zhang, G., Yao, M., Ma, S., Zhang, K., Wang, Y., Wang, Z., Liang, J., Dai, S., Jin, R., & Guan, F. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00605k · Cited by 19
CD47 expression in acute myeloid leukemia varies according to genotype
Marra, A., Akarca, A. U., Martino, G., Ramsay, A. D., Ascani, S., Perriello, V. M., O’Nions, J., Wilson, A. J., Gupta, R., Childerhouse, A., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283154 · Cited by 18
Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress
Chergui, A., & Reagan, J. L. (2023) · Cancers · doi:10.3390/cancers15164137 · Cited by 18
Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long‐Term Immune Memory by Reprogramming Tumor‐Associated Macrophages
Kim, Y., Lee, S., & Jon, S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300549 · Cited by 18
A new role for erythropoietin in the homeostasis of red blood cells
Arias, C. F., Valente-Leal, N., Bertocchini, F., Marques, S., Acosta, F. J., & Fernández-Arias, C. (2024) · Communications Biology · doi:10.1038/s42003-023-05758-2 · Cited by 18
Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells
Stefanidis, E., Semilietof, A., Pujol, J., Seijo, B., Scholten, K. B. J., Zoete, V., Michielin, O. A., Sandaltzopoulos, R., Coukos, G., & Irving, M. B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci161660 · Cited by 18
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
Sue, M., Tsubaki, T., Ishimoto, Y., Hayashi, S., Ishida, S., Otsuka, T., Isumi, Y., Kawase, Y., Yamaguchi, J., Nakada, T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304985 · Cited by 18
Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response
Gou, Q., Yan, B., Duan, Y., Guo, Y., Qian, J., Shi, J., & Hou, Y. (2024) · Advanced Science · doi:10.1002/advs.202412205 · Cited by 19
New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine
Gojo, I., & Karp, J. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0900 · Cited by 18
Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro
Yan, L., Yan, X.-Q., Yang, F., Yang, X., Jiang, X., Zhao, X., Zhu, B.-K., Liu, L., Qin, H., Liang, Y., et al. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.07.002 · Cited by 18
Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells
Irandoust, M. I., Zárate, J. Á., Hubeek, I., van Beek, E. M., Schornagel, K., Broekhuizen, A. J. F., Akyuz, M., van de Loosdrecht, A. A., Delwel, R., Valk, P. J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052143 · Cited by 18
Cytometric Profiling of CD133 + Cells in Human Colon Carcinoma Cell Lines Identifies a Common core Phenotype and Cell Type-specific Mosaics
Gemei, M., Noto, R. D., Mirabelli, P., & Vecchio, L. D. (2013) · The International Journal of Biological Markers · doi:10.5301/jbm.5000020 · Cited by 18
Stem cell technology in breast cancer: current status and potential applications
Chiotaki, R., Polioudaki, H., & Theodoropoulos, P. A. (2016) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s72836 · Cited by 18
Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway
Yang, Q., Chen, K., Zhang, L., Feng, L.-Y., Fu, G., Jiang, S., Bi, S., Lin, C., Zhou, Y., Zhao, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.003 · Cited by 18
Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells
Ko, Y. J., Lee, J. W., Kim, H., Cho, E., Yang, Y., Kim, I., Kim, S. H., & Kwon, I. C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.037 · Cited by 18
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes
Yanagisawa, B. L., Perkins, B. N., Karantanos, T., Levis, M. J., Ghiaur, G., Smith, B. D., & Jones, R. J. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106477 · Cited by 18
A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemia–Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia
Kang, K., Kim, H., Hur, W., Jung, J.-H., Jeong, S. J., Shin, H., Seo, D., Jeong, H., Choi, B. H., Hong, S., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002169 · Cited by 18
Interleukin 4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation
Peña-Martínez, P., Ramakrishnan, R., Högberg, C., Jansson, C., Nord, D. G., & Järås, M. (2021) · Haematologica · doi:10.3324/haematol.2020.270421 · Cited by 18

Authors: Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L.
Affiliations: Stanford Medicine (US)
Institute for Stem Cell Biology and Regenerative Medicine (US)
Stanford University (US)
Corresponding author: Majeti, Ravindra
Weissman, Irving L.
ORCID: Majeti, Ravindra
Chao, Mark P.
Alizadeh, Ash A.
Pang, Wendy W.
Jaiswal, Siddhartha
Gibbs, Kenneth D.
Weissman, Irving L.
Venue: Cell
Publisher: Elsevier BV
Published: 2009-07
Volume: 138
Issue: 2
Pages: 286-299
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2009.05.045
PMC: PMC2726837
OpenAlex: W2097126393
Cited by: 1,752
References: 47
Citations by year: 2026: 73 · 2025: 143 · 2024: 149 · 2023: 183 · 2022: 147 · 2021: 163 · 2020: 142 · 2019: 106 · 2018: 86 · 2017: 108 · 2016: 78 · 2015: 85 · 2014: 61 · 2013: 65 · 2012: 67
FWCI: 22.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1477 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (R01 CA86017, R01CA086017, T32CA009302)
National Institute of Allergy and Infectious Diseases (T32AI007290)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords: CD47, acute myeloid leukemia, leukemia stem cells, prognostic factors, anti-CD47 monoclonal antibody, phagocytosis, overall survival, engraftment, targeted therapy
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Phagocytosis, Prognosis, Receptors, Immunologic, Leukemia, Myeloid, Acute, Mice, CD47 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks